Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, tolerability, PK and PD study of MK-6194 in healthy Japanese participants
jRCT2051210183Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune colitis comparing MK-6194 arm with Placebo arm (2 arms). Primary endpoint: Adverse events. Started Mar 2022; status: completed.
02
Drugs
PT101
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2051210183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210183.